Norrie Disease (Pseudoglioma) antibody
Quick Overview for Norrie Disease (Pseudoglioma) antibody (ABIN634783)
Target
See all Norrie Disease (Pseudoglioma) (NDP) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purification
- Affinity purified
-
Immunogen
- NDP antibody was raised using a synthetic peptide corresponding to a region with amino acids DPRRCMRHHYVDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTV
-
-
-
-
Application Notes
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Comment
-
NDP Blocking Peptide, (ABIN937500), is also available for use as a blocking control in assays to test for specificity of this NDP antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of NDP antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- Norrie Disease (Pseudoglioma) (NDP)
-
Alternative Name
- NDP
-
Background
- NDP activates the canonical Wnt signaling pathway through FZD4 and LRP5 coreceptor. NDP plays a central role in retinal vascularization by acting as a ligand for FZD4 that signals via stabilizing beta-catenin (CTNNB1) and activating LEF/TCF-mediated transcriptional programs. NDP acts in concert with TSPAN12 to activate FZD4 independently of the Wnt-dependent activation of FZD4, suggesting the existence of a Wnt-independent signaling that also promote accumulation the beta-catenin (CTNNB1).
-
Molecular Weight
- 15 kDa (MW of target protein)
-
Pathways
- Sensory Perception of Sound
Target
-